Daiad-2/15 / StradBio - LARVOL DELTA

Conditional Immune Activation with Daiad-2/15: a Targeted, Hyperpotent IL-2/IL-15 Agonist with an Engineered Logic Gate (SITC 2025) - "Furthermore, Daiad-2/15 does not trans-activate target-negative cells, even when present in an admixed culture. Finally, Daiad technology enables an 'and' logic gate by targeting each of the inactive domains to different targets, such that immune cell activation and proliferation only occur when both targets are present on the same cell.Conclusions Together, our data suggest that Daiad-2/15 could potentiate the systemic delivery of a highly potent immune agonist to specific immune cells within the tumor microenvironment and draining lymph nodes in the absence of significant systemic toxicity."

Oncology • IL15 • IL2 • IL2RA